MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for ...
Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.
The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...
Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...
Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...
With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...
The 28-year-old defender is now supporting IBD research by the Royal Devon University Healthcare NHS Foundation Trust and the ...
In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is ...
Early in his career, San Francisco Giants first baseman J.T. Snow learned he had ulcerative colitis. Years later, it nearly ...
The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback